Kevin Kunzmann

The government-funded trial will seek to interpret the virus' transmissibility and infection, in order to inform vaccination and treatment strategies.

Preprint data show a US-based variant has come to represent more than 27% and 11% of all sequenced genomes in Louisiana and New Mexico, respectively, through mid-January.

A new study suggests nursing homes with more people of color are actually at three-fold greater risk of COVID-19 mortality.

New South Africa-based data show not only lessened protection versus the region's dominant variant, but a reduced vaccine-induced antibody neutralization.

The EUA follows the authorization for lone therapy bamlanivimab for adults and children at risk of severe COVID-19.

The two-dose vaccine's ineffective prevention of the more transmissible virus variant led to official seeking better options—and broader outcomes.

Pending advisory committee support and granted authorization, the adenovirus vaccine could become the first single-shot option in the US.

New preliminary phase 3 data show the two-dose vaccine may even hold benefit for single-dose use.

Cohort data shows 87% of infants born to mothers with asymptomatic or symptomatic COVID-19 have developed antibodies at birth.

A video breakdown of the past week's developments and news in leading vaccine candidates.

The to-be-reviewed assessment of real-world vaccine recipients suggests 51% greater efficacy with BNT162b2 after 13-24 days.

The findings accompany news that the company is working on new vaccines to address more transmissible SARS-CoV-2 variants.

After setbacks to its own vaccine candidate, the major drug developer has agreed to aide in production for Europe-bound doses.

New systematic review data suggest most patients who test positive without symptoms will remain asymptomatic over time.

A France-based assessment of the IL-1 inhibitor was ended early on the recommendation of the safety monitoring board early this year.

In a move being ill-received by clinicians, the COVID-19 vaccine producer is lessening the count of vials being supplied to the government through July.

The cabotegravir and rilpivirine formulation was approved on the basis of 2 trials assessing its viral suppression capability in 1100-plus adults with HIV.

Following the resignation of Stephen Hahn, MD, at the very end of the Trump administration, Janet Woodcock, MD, has been appointed as acting commissioner of the US Food and Drug Administration (FDA).

An online survey-based assessment showed older adults and minorities have been more likely to wear masks in public.

Current trial evidence is severely lacking for the at-risk group, but does clinical history suggest safety?

An interview on new survey data suggesting a majority of fertility and pregnant patients are not interested in the currently available vaccines.

State and federal officials confirmed Friday that promise for a reserve supply of vaccines meant for second doses is actually unavailable.

The ability to monitor, mitigate, and prevent new variant spread could influence the odds of majority immunity.

More transmissible variants are emerging quickly. An expert explains why it's expected, but concerning.

In vitro data suggest the more transmissible mutations of the virus are nonetheless prevented by the mRNA vaccine.

In the first week of 2021, the US is currently leading all countries in total vaccine administrations, despite state-level distribution setbacks.

A discussion around the relatively shocking effect of the virus on infants, and what's needed in long-term assessment of the patient group.

From vaccine studies to reopening institutions, pooled testing may be a hugely beneficial tool.

The global health agency provided current insights and advisories into 4 different variants observed during COVID-19 this year.

The newly published data show no patient given the two-dose mRNA vaccine has yet to report a case of severe COVID-19.